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Joseph Eschbach, a leading United States nephrologist recognized worldwide for his ground-breaking work on the anemia of chronic renal failure, died in his home in Bel-
levue, Washington, on 7 September 2007. Although 
he had never smoked, the cause of his death was 
lung cancer. Joe was born in Detroit in January 
1933. He attended Otterbein College in Ohio and 
obtained his medical degree from Jeﬀerson Medical 
College in Philadelphia in 1959. In 1963, he joined 
Belding Scribner’s Division of Nephrology at the 
University of Washington in Seattle as a research 
fellow. As was the custom, he sat down with Scrib 
to discuss possible research projects. He was told 
that only the topic of anemia of patients on chronic 
dialysis was left; all the other topics had been taken. 
This decision led him to begin working with John 
Adamson, then a research fellow in the Division 
of Hematology. They developed a partnership that 
lasted for more than thirty years.
At that time, the common belief was that the 
anemia in patients with chronic renal failure and 
dialysis patients was caused by bone marrow sup-
pression from inhibitors in uremic plasma. Joe soon 
observed that, even though uremic red blood cell 
production in these patients was regulated by small 
amounts of erythropoietin that their kidneys still 
were producing, the results of the studies on possi-
ble inhibitors were contradictory and controversial. 
At that time, dialysis patients generally required 
transfusion of one to three units of red blood cells 
every month or so to relieve the symptoms of tis-
sue hypoxia. However, transfusion was eﬀective 
only temporarily; increased the risk of hepatitis, 
of other infections, and of eﬀects of sensitization 
on possible transplantation; caused iron overload; 
suppressed endogenous erythropoietin production 
by the kidney; and resulted in transfusion depend-
ence. Once repeated transfusion was halted, many 
dialysis patients could maintain hematocrits in 
the region of 25 without the need for transfusion 
except after blood loss or infection. Joe and John 
also carried out extensive studies on iron metabo-
lism in chronic renal failure and showed that, con-
trary to previous views, intestinal iron absorption 
was normal in these patients.
Joe and John went on to develop an exquisite 
experimental model to study anemia in sheep made 
uremic by subtotal nephrectomy, some of which 
required dialysis. They used this model to exam-
ine the in vivo signiﬁcance of uremic inhibitors by 
infusing increasing amounts of erythropoietin-rich 
plasma from normal sheep made anemic by vene-
section or administration of phenylhydrazine into 
the uremic sheep, and compared the results with 
the eﬀects of infusing similar doses into the origi-
nal anemic normal sheep. Erythropoiesis, quanti-
ﬁed by reticulocyte response, plasma iron turnover, 
marrow transit time, and hemoglobin C synthesis, 
was similar in uremic sheep, whether dialyzed or 
not, and normal sheep. Red-cell production was 
increased, anemia was corrected, and the total dose 
of erythropoietin-rich plasma required depended 
on the degree of uremia. Dose–response curves 
were constructed; these and the identical response 
to the same amount of erythropoietin-rich plasma 
in uremic and anemic normal animals implied that 
no physiologically important erythropoietic inhibi-
tors existed in uremic plasma. This ﬁnding led to 
the conclusion that if erythropoietin became avail-
able for clinical use, it would correct the anemia 
associated with chronic kidney disease and end-
stage renal disease.
As a result of his work, Joe and patients at the 
Northwest Kidney Centers in Seattle, some of 
whom were from his private practice, were selected 
to carry out the ﬁrst studies in humans with recom-
binant human erythropoietin when it ﬁrst became 
available in December 1985. Transfusion require-
ments, hematocrit, ferrokinetics, and reticulocyte 
responses were monitored and showed dose-
dependent increases in erythropoiesis. Hematocrits 
rose to 35 or more, and ferrokinetics measured as 
erythron transferrin uptake increased three or four 
times over basal levels. So began the saga of eryth-
ropoiesis-stimulating agents (ESAs).
Joe was very involved in ensuring approval of 
erythropoietin by the United States Food and Drug 
Administration. He and I went to Washington to 
tell Congressional staﬀers about the beneﬁts of this 
exciting new drug and were taken aback that the 
ﬁrst question asked was, ‘How could this drug be 
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abused?’ This was something we had never consid-
ered. However, Congressional approval for its use 
in the Medicare End-Stage Renal Disease Program 
followed shortly, and the Centers for Medicare and 
Medicaid Services began to pay for erythropoietin 
for dialysis patients in 1989.
Joe had other clinical interests. In 1965, he was 
appointed director of the home-hemodialysis 
center at the University of Washington, a proto-
type for such centers. Because dialysis was not yet 
widely available, over the next several years more 
than 50 patients from elsewhere in the United 
States, Australia, the Philippines, Chile, and the 
Sudan came to Seattle with a family member and 
their doctor to be trained to do home hemodialy-
sis. This practice showed that home hemodialysis 
remote from a dialysis center and managed by an 
internist was safe and eﬀective. Joe also devel-
oped what he called an orientation unit at the 
Northwest Kidney Centers to provide concen-
trated patient education for all new patients dur-
ing the ﬁrst two months after starting dialysis.
Joe continued his interest in and research into 
renal anemia, erythropoietin, and iron metabo-
lism until shortly before his death. In 2003, he was 
appointed senior research advisor at the North-
west Kidney Centers.
He was in great demand to talk about renal 
anemia, erythropoietin, and his research all over 
the United States and in some 26 other countries 
around the world. He published in the range of 
150 articles, including 12 chapters in textbooks, 
and was coeditor of two books. When the National 
Kidney Foundation Dialysis Outcomes Quality 
Initiative was established in 1995, he was the ﬁrst 
chairman of the Anemia Work Group, and he con-
tinued in this role until 2001. Many honors came 
to him as a result of his work, including the David 
M Hume Award from the National Kidney Foun-
dation in 1995, election to the Institute of Medicine 
of the National Academy of Sciences in 1990, the 
Haviland Award of Excellence of the Northwest 
Kidney Centers in 1991, and the American Kidney 
Fund Torchbearer Award in 2003, and culminating 
in the International Society of Nephrology Amgen 
International Prize for Therapeutic Advancement 
in Nephrology in 2005. He shared this award with 
Dr. Eugene Goldwasser, who had done most of 
the original laboratory research on the identiﬁ-
cation and physiology of erythropoietin. Shortly 
before Joe’s death, the Northwest Kidney Centers 
and Kirin-Amgen Inc. established the Joseph W 
Eschbach Endowed Chair in Kidney Research at 
the University of Washington.
Joe was appointed clinical professor of medi-
cine at the University of Washington in 1975 and 
emeritus professor in 1994. He was director of 
the home-hemodialysis training center at the 
University of Washington from 1965 to 1972, 
president of the King County Medical Society 
in 1987, a member of the Northwest Kidney 
Centers Board of Trustees for many years and 
its president from 1985 to 1987, president of the 
Washington Association for Biomedical Research 
from 1991 to 2001, and senior research advisor at 
the Northwest Kidney Centers from 2003 until 
his death.
Remarkably, almost all of Joe’s research was 
carried out after he went into part-time private 
practice in nephrology and internal medicine in 
Seattle in 1965. This gave him a unique perspec-
tive, as he was personally responsible for a large 
number of dialysis patients over the years. Even 
more remarkable, while many practicing physi-
cians in Seattle knew Joe was a great doctor, they 
knew him as a humble person, and few of them 
realized that he was so well known throughout 
the world for his research.
He was described by his colleagues and patients 
as gentle, caring, considerate, and ethical, and his 
patients said he took the extra time to truly listen 
to them and understand their concerns. As one 
of his colleagues said, “Joe was the kind of doctor 
that a doctor would want as his doctor.”
In addition, Joe had many other interests. Music 
was important in his life from an early age; he 
was an accomplished singer and, on one occa-
sion, sang in the chorus of the Seattle Opera’s Ring 
Cycle. He was an ardent skier who had a retire-
ment wish to ski every slope in the western United 
States. Other interests included woodworking, 
sculpture, squash, golf, theology, and reading. 
He was also very much a family man, married to 
Mary Ann for ﬁfty years and with three children 
and ﬁve grandchildren.
To describe someone as a Renaissance man 
has become something of a hackneyed expres-
sion. However, it certainly ﬁts as a description of 
Joseph Eschbach and his life.
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